Patents Assigned to Hadasit Medical Research Services & Development Ltd.
  • METHODS OF SELECTING RETINAL PIGMENTED EPITHELIAL CELLS
    Publication number: 20170199190
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Application
    Filed: March 28, 2017
    Publication date: July 13, 2017
    Applicants: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Nurit YACHIMOVICH-COHEN, Limor MATZRAFI
  • Tissue regeneration membrane
    Patent number: 9669136
    Abstract: The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: June 6, 2017
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Michael Friedman, Yoel Sasson, Ada Grin, Rami Mosheiff, Jacob Rachmilewitz
  • Methods of selecting retinal pigmented epithelial cells
    Patent number: 9658216
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: May 23, 2017
    Assignees: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan Reubinoff, Nurit Yachimovich-Cohen, Limor Matzrafi
  • TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS WITH DELAYED-RELEASE 6-MERCAPTOPURINE
    Publication number: 20170105996
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering front type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 20, 2017
    Applicants: Teva Pharmaceutical Industries, Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron ILAN, Doina Cosma ROMAN, Michael HAYDEN, Einat AMIT-ROMACH
  • Methods and compositions for treating viral infections
    Patent number: 9616067
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: April 11, 2017
    Assignees: Hadasit Medical Research Services and Development Ltd., The Hong Kong University of Science and Technology
    Inventors: Richard K. Haynes, Dana G. Wolf
  • METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS
    Publication number: 20170071952
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Application
    Filed: November 25, 2016
    Publication date: March 16, 2017
    Applicants: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Richard K. HAYNES, Dana G. WOLF
  • IMPROVED CELL COMPOSITIONS AND METHODS FOR CANCER THERAPY
    Publication number: 20160333072
    Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham RUTENBERG, Ronny UZANA, Michal LOTEM, Arthur MACHLENKIN, Galit EISENBERG, Tamar PERETZ-YABLONSKY, Shoshana FRANKENBURG, Roni ENGELSTEIN
  • MIR-122* AS AN ACTIVE MICRO-RNA, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
    Publication number: 20160333344
    Abstract: Provided is a miR-122* as a functional microRNA molecule, compositions including the same and uses thereof for treatment of various conditions, such as, cancer.
    Type: Application
    Filed: January 6, 2015
    Publication date: November 17, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Hilla GILADI, Alina SIMERZIN, Yael HANTZ, Sagit ARBEL ALON, Eithan GALUN
  • ALGINATE BIOMATERIALS FOR THE TREATMENT OF HEPATIC DISORDERS
    Publication number: 20160317570
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Application
    Filed: July 10, 2016
    Publication date: November 3, 2016
    Applicants: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron ILAN, Gadi LALAZAR, Eyal SHTEYER, Ami BEN-YA'ACOV, Smadar COHEN, Tsiona ELKAYAM
  • Compositions and methods for amelioration and prevention of drug-induced toxicity
    Patent number: 9474763
    Abstract: Pharmaceutical compositions including combinations of protective agents selected from isosilybin B, methylsulfonylmethane (MSM), phosphatidylcholine, cysteine (Cys), seleno-cysteine (Se-Cys), ribose-cysteine (RibCys), N-acetylcysteine (NAC), N-acetylcysteine-amide (AD4), methionine (Met) and S-adenosylmethionine (SAM) for reducing and/or preventing drug-induced toxicity, such as acetaminophen-induced toxicity. The compositions may be formulated with or without acetaminophen, and accordingly may be used as safe formulations of acetaminophen with reduced risk of causing liver damage, or as an antidote for the treatment of acetaminophen overdose. Methods for treating acetaminophen intoxication.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: October 25, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Josef Mograbi, Yaron Ilan
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 9469855
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: October 18, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • Alginate biomaterials for the treatment of hepatic disorders
    Patent number: 9387222
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: July 12, 2016
    Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Yaakov, Smadar Cohen, Tsiona Elkayam
  • ALLOGENEIC TUMOR CELL VACCINATION
    Publication number: 20160175416
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 23, 2016
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tamar PERETZ, Michal LOTEM, Arthur MACHLENKIN, Shoshana FRANKENBURG, Inna BEN DAVID, Anna KUZNETZ, Yael GELFAND, Galit EISENBERG, Merav DARASH YAHANA
  • Targeting of innate immune response to tumor site
    Patent number: 9358307
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: January 25, 2009
    Date of Patent: June 7, 2016
    Assignees: GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • DEVICES AND METHODS FOR PERCUTANEOUS ENDOSCOPIC GASTROSTOMY AND OTHER OSTOMY PROCEDURES
    Publication number: 20160143816
    Abstract: Ostomy tubes, particularly gastrostomy tubes, with improved retention means are provided. More specifically, retention structures, such as bolsters, for gastrostomy tubes are provided, configured to removably assemble to one end of a gastrostomy tube to facilitate replacement and removal of the tube. The retention structures provided herein may comprise one or more removably assembled retention elements. Further provided are gastrostomy tubes comprising such retention structures, and methods for percutaneous endoscopic gastrostomy utilizing same.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 26, 2016
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Ishay BENURI-SILBIGER
  • Allogeneic tumor cell vaccination
    Patent number: 9301998
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: April 5, 2016
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • Assay and kit and device for removing amylase from body fluids
    Patent number: 9297804
    Abstract: The invention is directed to separation of amylase from body fluid by contacting said body fluid with starch under conditions enabling binding between the amylase and the starch, separating between the starch-amylase bound complexes and the free components, thereby removing the bound amylase, and collecting the non-bound components.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: March 29, 2016
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Aaron Palmon, Omer Doitch, Doron Aframian
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 9243294
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NLGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 26, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • Endodontic files and method of preparation thereof
    Patent number: 9155595
    Abstract: The present invention provides a selective coating of an endodontic file, in which the distal end of the file is uncoated or alternatively leaving the outermost part of the blades of the distal end portion uncoated. The distribution of the nanoparticles is thus non uniform along the surface of the file leaving only a part of the file coated. In the present invention, the distal end of the device being subjected to the highest torque is either uncoated at all, or has a coated core and uncoated blades.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: October 13, 2015
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Reshef Tenne, Meir Redlich, Adi Ram-Adini, Yishay Feldman, Gili Naveh, Joshua Moshonov, Boaz Shay
  • tPA mutant in the treatment of acute brain injury and neurodegenerative disorders
    Patent number: 9072737
    Abstract: The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser481 to Ala mutant of tPA and to compositions and combinations thereof for the treatment of stroke, acute brain injury and neurodegenerative disorders. The invention further provides methods and kits for the treatment of said disorders.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: July 7, 2015
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Abd Higazi, Nuha Hijazi